Biotech midweek sentiment cools after 2026 rally
Biotech’s 2026 rally cooled this week despite major clinical updates. Definium Therapeutics (DFTX), Vera Therapeutics (VERA) and GSK (GSK) led the early news cycle, while Ultragenyx Pharmaceutical (RARE) faces a key remaining FDA decision.